Search results - 137 results
Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.
Publication Type: Peer reviewed scientific article Authors: M. Arbyn; Smith, Sara B; Temin, Sarah; Sultana, Farhana; Castle, Philip; Collaboration on Self-Sampling and HPV Testing Source: BMJ, ...
Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials.
Publication Type: Peer reviewed scientific article Authors: M. Arbyn; Lan Xu Source: Expert Rev Vaccines, Volume 17, Issue 12 (2018) Keywords: Cervical cancer; HPV vaccines; meta-analysis; ...
Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
Cervical Neoplasms Abstract: In 2012, VAL idation of human papillomavirus (HPV) GEN otyping T ests (VALGENT) was initiated to provide a formalized and uniform study framework for comparison and validation of ...
Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
(hrHPV) types is more effective than cytology-based screening. This study completes the diagnostic accuracy assessment conducted previously within the framework of VALGENT-2 (Validation of HPV genotyping ...
VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples
cervical precancer. However, insufficient evidence is available for specific HPV assay/self-sample device combinations. OBJECTIVES: The VALHUDES protocol is designed as a diagnostic test accuracy study that ...
Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework.
Neoplasms Abstract: In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping performance of the INNO-LiPA HPV Genotyping II (INNO-LiPA) within the VALGENT-3 framework. ...
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
causally linked with the development of cervical precancer and cancer. HPV types 16 and 18 cause approximately 70% of cervical cancers worldwide. OBJECTIVES: To evaluate the harms and protection of ...
Evaluation of the clinical performance of the HPV-Risk assay using the VALGENT-3 panel.
Abstract: Human papillomavirus (HPV) testing is being increasingly incorporated into cervical cancer screening. VALGENT (VAL idation of HPV GEN otyping Tests) is a framework designed to evaluate the clinical ...
Defining optimal triage strategies for hrHPV screen positive women- an evaluation of HPV 16/18 genotyping, cytology and p16/Ki-67 cyto-immunochemistry.
Lynne; Govan, Lynn; Black, Janice; Palmer, Tim; M. Arbyn Source: Cancer Epidemiol Biomarkers Prev (2017) Abstract: BACKGROUND: Several options for the triage of high-risk HPV screen positive (hrHPV+) women ...
Role of mucosal high-risk human papillomavirus types in head and neck cancers in central India.
Paul; Sankaranarayanan, Rengaswamy; Pillai, Madhavan Radhakrishna; Gangane, Nitin; Tommasino, Massimo; HPV-AHEAD study group Source: Int J Cancer, Volume 141, Issue 1, p.143-151 (2017) Keywords: Adult ...